Dr Jitendra Singh Inaugurates Recombinant Cell Facility At BRIC-RGCB
ECONOMY & POLICY

Dr Jitendra Singh Inaugurates Recombinant Cell Facility At BRIC-RGCB

Union Minister Dr Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Keralam, noting the facility will accelerate target-specific drug discovery and support medical and agricultural genomics. The minister also announced the foundation stone for a dedicated GMP facility and released a book by Professor V.P.N. Nampoori. The new facility was developed with investment of Rs 60 crores, equivalent to 600 million (600 mn) and is intended to serve academia, industry and healthcare innovators.

He outlined a vision for a bio-driven economy supported by the BioE3 Policy, which aims to align economy, environment and employment to boost biomanufacturing. He cited that India’s bioeconomy has grown 16-fold in the past decade from 10 billion US dollars (10 bn US dollars) to nearly 166 billion US dollars (166 bn US dollars) and is aiming for 300 billion US dollars (300 bn US dollars). The policy emphasis is intended to anticipate and enable a shift towards large-scale biomanufacturing and bio-based industries.

He highlighted growth in entrepreneurship with the number of biotechnology start-ups rising from about 50 to 70 in 2014 to over 11,000, reflecting an expanding innovation ecosystem supported by policy reforms and funding for deep-tech start-ups. The Department of Biotechnology has funded the new recombinant cell facility through long-term programmes. He emphasised the rising burden of non-communicable diseases and the institute's research in cancer biology, preventive healthcare and HPV vaccination evidence.

He announced that the GMP facility will support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy, and will operate on a pay-and-use basis for biotech industries with implementation in two phases and total DBT investment of Rs 80 crores, equivalent to 800 million (800 mn). He called for deeper collaboration among research institutions, private industry and emerging sectors such as nuclear medicine and deep-ocean research, encouraging coastal states to align biotechnology with national missions. He urged young researchers to utilise the expanding ecosystem and assured continued government support for innovation and interdisciplinary collaboration.

Union Minister Dr Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Keralam, noting the facility will accelerate target-specific drug discovery and support medical and agricultural genomics. The minister also announced the foundation stone for a dedicated GMP facility and released a book by Professor V.P.N. Nampoori. The new facility was developed with investment of Rs 60 crores, equivalent to 600 million (600 mn) and is intended to serve academia, industry and healthcare innovators. He outlined a vision for a bio-driven economy supported by the BioE3 Policy, which aims to align economy, environment and employment to boost biomanufacturing. He cited that India’s bioeconomy has grown 16-fold in the past decade from 10 billion US dollars (10 bn US dollars) to nearly 166 billion US dollars (166 bn US dollars) and is aiming for 300 billion US dollars (300 bn US dollars). The policy emphasis is intended to anticipate and enable a shift towards large-scale biomanufacturing and bio-based industries. He highlighted growth in entrepreneurship with the number of biotechnology start-ups rising from about 50 to 70 in 2014 to over 11,000, reflecting an expanding innovation ecosystem supported by policy reforms and funding for deep-tech start-ups. The Department of Biotechnology has funded the new recombinant cell facility through long-term programmes. He emphasised the rising burden of non-communicable diseases and the institute's research in cancer biology, preventive healthcare and HPV vaccination evidence. He announced that the GMP facility will support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy, and will operate on a pay-and-use basis for biotech industries with implementation in two phases and total DBT investment of Rs 80 crores, equivalent to 800 million (800 mn). He called for deeper collaboration among research institutions, private industry and emerging sectors such as nuclear medicine and deep-ocean research, encouraging coastal states to align biotechnology with national missions. He urged young researchers to utilise the expanding ecosystem and assured continued government support for innovation and interdisciplinary collaboration.

Related Stories

Gold Stories

Next Story
Products

Koemmerling opens Navi Mumbai experience centre

Koemmerling, a brand of the profine Group, has expanded its presence in the Mumbai metropolitan region with the opening of a new experience centre in Navi Mumbai and launched its Allure S46 minimal sliding door system for the Indian market.Located in CBD Belapur, the facility was inaugurated by Peter Mrosik, Owner and CEO, profine Group, along with Farid Khan, Chairman and Managing Director, profine India, and Kamal Bajaj, CEO, profine India.The company said the new centre will showcase its portfolio of uPVC and aluminium window and door systems to architects, developers and homeowners.The ina..

Next Story
Products

India's waterproofing market nears Rs 150 bn milestone

India's waterproofing industry is approaching a market size of Rs 150 billion and is expected to surpass the $2 billion milestone, according to speakers at the 2nd India International Waterproofers Conference & Expo 2026 organised by the Waterproofers Association of India (WAI) in New Delhi.The two-day event brought together more than 20 speakers, 55 international delegates and 53 exhibition booths, with discussions focusing on climate-resilient construction, advanced waterproofing technologies and international collaboration.Inaugurating the event, Durga Shanker Mishra, former Secretary, ..

Next Story
Real Estate

Dilip Buildcon Q1 FY27 Revenue at Rs 23.78 billion

Dilip Buildcon Limited reported consolidated revenue from operations of Rs 2,378 crore in Q1 FY27, along with EBITDA of Rs 429 crore and profit after tax of Rs 128 crore.Consolidated EBITDA margin stood at 18.1%, improving from 17.1% in Q4 FY26. On a standalone basis, revenue from operations was Rs 1,930 crore, EBITDA stood at Rs 199 crore and PAT was Rs 39 crore, with an EBITDA margin of 10.3%.The company’s order book stood at Rs 27,691 crore as of 30 June 2026, compared with Rs 28,830 crore as of 31 March 2026. Roads and highways accounted for 17.1% of the order book, irrigation and water ..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement